CSI’s ViperCross Peripheral Support Catheter Launched in the United States

September 29, 2021—Cardiovascular Systems, Inc. (CSI) announced the commercial launch of the company’s ViperCross peripheral support catheter, which recently received FDA 510(k) clearance. Billy J. Kim, MD, with The Surgical Clinic in Nashville, Tennessee, treated the first patient with the device.

“ViperCross offers the right balance of support and flexibility to successfully navigate tortuous anatomy and cross challenging lesions,” commented Dr. Kim in the company’s press release. “In addition, ViperCross provides excellent guidewire support and facilitates easy guidewire exchange.”

As noted in the company’s press release, the 018/035 ViperCross support catheters are intended to be used in conjunction with steerable guidewires to access discrete regions of the peripheral vasculature.

The 014 ViperCross support catheters are intended to be used to access discrete regions of the peripheral and/or coronary vasculature.

ViperCross catheters may be used to facilitate placement and exchange of guidewires and other interventional devices and to subselectively infuse/deliver diagnostic and therapeutic agents, advised the company.

On March 22, CSI announced that it acquired the peripheral support catheters from WavePoint Medical, LLC, that it would market as the ViperCross.